These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. In-scaffold restenosis in a previous left main bifurcation lesion treated with bioresorbable scaffold v-stenting. Miyazaki T; Panoulas VF; Sato K; Kawamoto H; Naganuma T; Latib A; Colombo A JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e7-e10. PubMed ID: 25499306 [No Abstract] [Full Text] [Related]
8. Very Late Restenosis After Bioresorbable Scaffold Implantation Due to Simultaneous External Compression of the Scaffold and Intrascaffold Tissue Growth. Tanaka A; Ruparelia N; Kawamoto H; Latib A; Colombo A JACC Cardiovasc Interv; 2016 Jan; 9(2):e15-7. PubMed ID: 26723762 [No Abstract] [Full Text] [Related]
9. Bioresorbable vascular scaffolds in left main coronary artery disease. Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148 [TBL] [Abstract][Full Text] [Related]
10. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives. Kitabata H; Waksman R; Warnack B Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760 [TBL] [Abstract][Full Text] [Related]
11. Bioresorbable vascular scaffolds for a long diffuse coronary lesion: insights from optical coherence tomography at 25-month follow-up. Basavarajaiah S; Naganuma T; Watkin R Kardiol Pol; 2018; 76(5):928. PubMed ID: 29756198 [No Abstract] [Full Text] [Related]
12. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932 [TBL] [Abstract][Full Text] [Related]
13. Positive Vessel Remodeling and Appearance of Pulsatile Wall Motion at Long-Term Follow-Up After Bioresorbable Scaffold Implantation in a Chronic Total Occlusion. Tanaka A; Ruparelia N; Kawamoto H; Latib A; Colombo A JACC Cardiovasc Interv; 2015 Oct; 8(12):1635-7. PubMed ID: 26386767 [No Abstract] [Full Text] [Related]
14. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421 [TBL] [Abstract][Full Text] [Related]
15. Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). Ishibashi Y; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Garcia-Garcia HM; Bartorelli AL; Whitbourn R; Chevalier B; Abizaid A; Ormiston JA; Rapoza RJ; Veldhof S; Onuma Y; Serruys PW JACC Cardiovasc Interv; 2015 Nov; 8(13):1715-26. PubMed ID: 26585622 [TBL] [Abstract][Full Text] [Related]
16. Contained coronary rupture following bioresorbable scaffold implantation in a small vessel. Kawamoto H; Jabbour RJ; Tanaka A; Latib A; Colombo A Int J Cardiol; 2016 Apr; 209():24-5. PubMed ID: 26878469 [No Abstract] [Full Text] [Related]
18. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel. Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653 [No Abstract] [Full Text] [Related]
19. First-in-man implantation of bioresorbable vascular scaffold in left internal mammary artery graft. Deora S; Shah S; Patel T J Invasive Cardiol; 2014 Feb; 26(2):92-3. PubMed ID: 24486669 [TBL] [Abstract][Full Text] [Related]
20. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]